CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 264 target
Drug / intervention
TG-873870(Nemonoxacin)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00434291
NCT00434291Phase 2Completed
CompareCT.gov

A Randomized, Double-Blind, Comparative, Multi-Center Study of the Safety and Efficacy of TG-873870(Nemonoxacin) Versus Levofloxacin in Adult Patients With Community-Acquired Pneumonia (CAP)

TaiGen Biotechnology Co., Ltd.·interventional·Posted Feb 13, 2007·Updated Nov 25, 2009

In Brief

A Phase 2 clinical trial evaluating TG-873870(Nemonoxacin) for Community-Acquired Pneumonia. Completed, enrolled 264 participants across 20 sites in 2 countries.

Detailed Summary

This study will test the safety and efficacy of TG-873870(Nemonoxacin) compared with Levofloxacin in adult patients with Community-Aquired Pneumonia(CAP)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommunity-Acquired Pneumonia
CountriesSouth Africa, Taiwan
CollaboratorsQuintiles, Inc.

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2007
Enrollment StartDec 1, 2006
Study CompletionAug 1, 2007
TodayJul 2, 2026
Posted 19.4 years ago

Interventions

TG-873870(Nemonoxacin)drug